Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of EV71 Vaccine in Healthy Infants and Children
NCT05099029Phase 3Completed
- Sponsor
- Enimmune
- Start
- Jun 2018
- Primary completion
- Jul 2024
- Modality
- Whole Inactivated Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in enterovirus 71 infection comparing EV71 Vaccine with Placebo (2 arms). Primary endpoints: Incidence rate of Hand, Foot and Mouth disease caused by EV71 at 2 years and Serum neutralizing antibody titers at 28 days. Started Jun 2018; status: completed.
02
Drugs
inactivated EV71 vaccine
03
Conditions
enterovirus 71 infection
Beyond the preview
Go deeper on NCT05099029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099029.